Biotech entity
All 2 tracked stories fall under one category: pharma. ATG-201 is most often covered alongside UCB, which appears in 2 of these 2 stories. Across a 17-day span, the pace is roughly 0.8 stories per week. Source depth averages 2.5 original sources per story, versus 3.4 across the same-window beat baseline.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. ATG-201 is most often covered alongside UCB, which appears in 2 of these 2 stories. Across a 17-day span, the pace is roughly 0.8 stories per week. Source depth averages 2.5 original sources per story, versus 3.4 across the same-window beat baseline. Their average consequence score of 6.5 runs above the beat's 6.1 for that window. This profile follows 2 Biotech stories mentioning ATG-201 across the period from March 4, 2026 to March 20, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 256 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ATG-201. Shared-story counts are live from our verified record — not editorial picks.
Profitability Target
Antengene aims to achieve its first full year of profitability.
AACR 2026
Antengene scheduled to present data on next-generation ADCs and TCEs.
2025 FY Results
Company announces full-year results and confirms shift toward 2026 profitability.
Investor Briefings
Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.
UCB Partnership
Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.
Global License Agreement
Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.
Regulatory Filings
Planned submission of clinical trial applications for ATG-201 in China and Australia.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
ATG-201 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
